{"filing":{"accession_number":"0001193125-26-235469","cik":"0001426800","ticker":"ASMB","company_name":"ASSEMBLY BIOSCIENCES, INC.","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"asmb-20260522.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526235469/asmb-20260522.htm"},"events":[{"id":10535,"run_id":9238,"accession_number":"0001193125-26-235469","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Assembly Biosciences announced a material expansion of its lead clinical candidate ABI-6250 from HDV infection into two additional cholestatic liver disease indications (PBC and PSC), with Phase 2 trials planned for Q4 2026 and Q1 2027, supported by preclinical data and constructive FDA pre-IND meeting feedback.","company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","filing_date":"2026-05-22","form":"8-K","submitted_at":null,"items":[{"id":6868,"accession_number":"0001193125-26-235469","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Assembly Biosciences announced expansion of clinical development for ABI-6250 from HDV infection into two additional cholestatic liver disease indications (PBC and PSC), representing a material broadening of the drug candidate's development program. This strategic expansion of clinical scope is material to investors assessing the company's pipeline and commercial potential, but does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, or executive change).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:26:41.277116+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6869,"accession_number":"0001193125-26-235469","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Assembly Biosciences discloses plans to expand clinical development of its lead candidate 6250 from chronic HDV infection into two additional indications (PBC and PSC), with Phase 2 trials planned for Q4 2026 and Q1 2027. This represents a material expansion of the clinical pipeline and development strategy supported by preclinical data, Phase 1a findings, and constructive FDA pre-IND meeting feedback. While not fitting neatly into the specific event categories (not an earnings release, M\u0026A activity, impairment, or litigation), this material clinical development milestone would affect a reasonable investor's assessment of the company's pipeline and future prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:26:41.277116+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6868,"accession_number":"0001193125-26-235469","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Assembly Biosciences announced expansion of clinical development for ABI-6250 from HDV infection into two additional cholestatic liver disease indications (PBC and PSC), representing a material broadening of the drug candidate's development program. This strategic expansion of clinical scope is material to investors assessing the company's pipeline and commercial potential, but does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, or executive change).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:26:41.277116+00:00","company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","filing_date":"2026-05-22"},{"id":6869,"accession_number":"0001193125-26-235469","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Assembly Biosciences discloses plans to expand clinical development of its lead candidate 6250 from chronic HDV infection into two additional indications (PBC and PSC), with Phase 2 trials planned for Q4 2026 and Q1 2027. This represents a material expansion of the clinical pipeline and development strategy supported by preclinical data, Phase 1a findings, and constructive FDA pre-IND meeting feedback. While not fitting neatly into the specific event categories (not an earnings release, M\u0026A activity, impairment, or litigation), this material clinical development milestone would affect a reasonable investor's assessment of the company's pipeline and future prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:26:41.277116+00:00","company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","filing_date":"2026-05-22"}]}